{"id":"W2137101132","doi":"10.1136/annrheumdis-2013-204655","title":"Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","year":2014,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":658,"is_retracted":false,"has_abstract":true,"ca_institutions":"Memorial University of Newfoundland","funders":"Astellas Pharma; Incyte; Eli Lilly and Company; CSL Behring; Tufts Medical Center; Celgene; Alexion Pharmaceuticals; Amgen; Pfizer; Regeneron Pharmaceuticals; Novo Nordisk; Teva Pharmaceutical Industries; GlaxoSmithKline","keywords":"Medicine; Ustekinumab; Psoriatic arthritis; Internal medicine; Placebo; Psoriasis; Psoriasis Area and Severity Index; Rheumatology; Clinical endpoint; Gastroenterology; Arthritis; Surgery; Tumor necrosis factor alpha; Randomized controlled trial; Immunology; Adalimumab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003535969,0.0003140908,0.001254798,0.00005441286,0.0001980701,0.00002242537,0.0001754047,0.0001003511,0.00002072124],"category_scores_gemma":[0.001023267,0.000135063,0.0003031136,0.0001632609,0.0007821884,0.00007690393,0.000163784,0.0001340163,3.872458e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001117231,"about_ca_system_score_gemma":0.00005852517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007485039,"about_ca_topic_score_gemma":0.00002172209,"domain_scores_codex":[0.9976346,0.0004510331,0.0008603291,0.0003603521,0.0004117946,0.0002819008],"domain_scores_gemma":[0.9973615,0.001195171,0.0008120383,0.0003402558,0.0001717944,0.0001192693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7413924,0.002762151,0.2430559,0.00006508583,0.0008788579,0.000001189196,0.0003232286,0.00000853852,0.00006616644,0.00002132685,0.00001571331,0.01140948],"study_design_scores_gemma":[0.4733727,0.001241294,0.5239388,0.0007385466,0.000142855,0.000001142018,0.00008553296,0.0000792971,0.0002733604,0.00004060657,0.000004665172,0.00008121107],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925889,0.0009513539,0.000003000354,0.0003816835,0.0001182158,0.005148034,0.0007786347,0.000006222617,0.00002391818],"genre_scores_gemma":[0.9970071,0.002750947,0.00002858692,0.0000445132,0.00002252298,0.0000745949,0.00004978177,0.00001346955,0.000008450888],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2808829,"threshold_uncertainty_score":0.5507711,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03503453515663549,"score_gpt":0.303285057102635,"score_spread":0.2682505219459995,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}